| Karen Sachiko Kato, MD | |
|
784 14th Ave, Longview, WA 98632-2315 | |
| (360) 425-6111 | |
| (360) 636-2149 |
| Full Name | Karen Sachiko Kato |
|---|---|
| Gender | Female |
| Speciality | Pediatrics - Adolescent Medicine |
| Location | 784 14th Ave, Longview, Washington |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1598756967 | NPI | - | NPPES |
| 126615 | Other | WA | WA LABOR & INDUSTRIES |
| 8454605 | Medicaid | WA | |
| 283564 | Medicaid | OR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2080A0000X | Pediatrics - Adolescent Medicine | MD00020759 (Washington) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Karen Sachiko Kato, MD 784 14th Ave, Longview, WA 98632-2315 Ph: (360) 425-6111 | Karen Sachiko Kato, MD 784 14th Ave, Longview, WA 98632-2315 Ph: (360) 425-6111 |
News Archive
Researchers from Rutgers Cancer Institute of New Jersey, the state's only National Cancer Institute-designated Comprehensive Cancer Center, evaluated the frequency of SARS-CoV-2, the virus that causes COVID-19, on various environmental surfaces in outpatient and inpatient hematology/oncology settings located within Rutgers Cancer Institute and Robert Wood Johnson University Hospital, an RWJBarnabas Health facility.
BioNeutral Group, Inc., a specialty technology-based life science company, today announced it has signed a "Stand Still" agreement with a leading pharmaceutical company, DFB Pharmaceuticals, Inc. (DFB).
Boehringer Ingelheim announced today that the US Food and Drug Administration (FDA) has approved a new indication for MICARDIS® (telmisartan) for the reduction of the risk of myocardial infarction (heart attack), stroke, or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors. MICARDIS® is the first treatment in its class to be approved for this indication.
Octapharma USA researchers presented new stringent, objective criteria used in the evaluation of hemostatic efficacy in the treatment of von Willebrand disease and reported on their application of these criteria in clinical trials during the recently completed National Hemophilia Foundation Annual Meeting.
› Verified 5 days ago
Daryl William Linnell, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 784 14th Ave, Longview, WA 98632 Phone: 360-425-6111 Fax: 360-636-1297 | |
Pamela M Roberts, ARNP Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 971 11th Ave, Longview, WA 98632 Phone: 360-577-1771 Fax: 360-423-1405 | |
Dr. John Leigh Ey, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 971 11th Ave, Longview, WA 98632 Phone: 360-423-6140 Fax: 360-423-1405 | |
Mary Jane Hall, ARNP Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 971 11th Ave, Longview, WA 98632 Phone: 360-577-1771 Fax: 360-423-1405 | |
Dr. Kenneth R Wu, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 971 11th Ave, Longview, WA 98632 Phone: 360-423-6140 Fax: 360-423-1405 | |
Dr. Jennifer Louise Saxer, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 784 14th Ave, Longview, WA 98632 Phone: 360-425-6111 Fax: 360-636-1297 | |
Michael Lee Kubitz, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 784 14th Ave, Longview, WA 98632 Phone: 360-425-6111 Fax: 360-636-1297 |